On the Couch with Dr Liz Dallimore (Argenica): Phase Two, FDA and What's Ahead
About this episode
Henry Jennings interviews Dr Liz Dallimore about Argenica Therapeutics' phase two trial results and future plans.
In this episode of On the Couch, Henry Jennings speaks with Dr Liz Dallimore, CEO of Argenica Therapeutics (ASX: AGN). Fresh from presenting phase two trial data at a major international stroke conference, Liz walks through what the results showed, why neuroprotection is such a difficult space, and what the path forward looks like for the company. — Marcus Today – Daily Market Insights Marcus Today provides clear, practical commentary for self-directed investors – covering markets, portfolios...
Topics covered
- neuroprotection
- clinical trials
- investing
- healthcare
- stroke treatment
More episodes of On the Couch
Explore listener stats, chart rankings, contacts and more on the On the Couch podcast page.